A streamlined approach for gene editing in non-obese diabetes (NOD) mice via CRISPR/Cas9.

In the pursuit of understanding human autoimmune diseases like Type 1 diabetes (T1D), researchers rely heavily on animal models. Among the most vital is the non-obese diabetic (NOD) mouse. This strain spontaneously develops the same insulin-destroying immune responses seen in humans. However, creating genetically modified versions of these mice has historically been a logistical nightmare.

For years, the standard practice involved creating a genetic modification in a "permissive" mouse strain (one that is easier to manipulate, like C57BL6). Researchers then spent nearly two years performing repeated backcrossings (breeding the modified mouse with pure NOD mice over many generations). This process moves the mutation into the NOD background. This method is agonizingly slow and consumes massive amounts of laboratory resources.

A new study by Cho et al. breaks this bottleneck. They established a streamlined protocol for direct CRISPR/Cas9 gene editing in NOD embryos. This approach could reduce the timeline for creating new models from 24 months to just 12–14 weeks.

The bottleneck of the NOD background

The difficulty in working with NOD mice is not just genetic complexity. It is also a matter of biological fragility. Unlike the hardy C57BL6 strain, NOD mice suffer from progressive autoimmunity starting at 2–3 weeks of age. This leads to several systemic failures in traditional genetic engineering workflows:

1. Short reproductive lifespan: As the mice develop hyperglycemia (high blood sugar levels), their health declines. This makes them difficult to maintain for long-term breeding programs.
2. Low breeding efficiency: NOD mice exhibit naturally low mating rates compared to standard lab strains.
3. Embryo instability: Recovering healthy, injectable embryos from NOD females is difficult. Their unique hormonal responses and slower embryonic development complicate the process.

Previously, researchers tried to bypass these issues using in vitro fertilization (IVF). This is the process of fertilizing eggs in a laboratory setting rather than through natural mating. While IVF can produce more embryos, the authors note it is technically demanding. It requires highly specialized skills and often necessitates grueling work schedules. Some protocols require recovering embryos at 2:00 AM to meet strict microinjection windows.

A synchronized protocol for direct editing

The researchers developed a simplified approach. It relies on natural mating and optimized hormonal stimulation to produce robust embryos. The core of their architecture rests on a precisely timed superovulation (the process of stimulating a female to release a larger-than-normal number of eggs) regime.

The workflow follows a specific temporal logic: 1. Hormonal Induction: 4-week-old NODShiLtJ females receive an injection of Pregnant Mare Serum Gonadotropin (PMSG) between 8:00 AM and 12:00 PM. 2. Trigger Injection: Exactly 46 hours later, the females receive Human Chorionic Gonadotropin (HCG). 3. Natural Mating: The females are mated with males immediately after the HCG injection. 4. Timed Recovery: Embryos are recovered 15 hours after mating. This timing is critical. The authors observed that NOD embryos develop slowly. Waiting allows the pronuclei (the membrane-bound structures containing genetic material) to become large and visible [Figure 1c].

Once recovered, the researchers used two primary delivery methods for the CRISPR components (the Cas9 enzyme and guide RNAs): pronuclear microinjection, where a physical needle delivers the cargo directly into the nucleus, and electroporation, where brief electrical pulses create temporary pores in the embryo membrane.

Efficiency gains in knockout and knock-in

The efficacy of this method was validated across several genetic tasks. The authors measured success by the percentage of liveborn pups that carried the intended genetic change.

For gene knockout (KO) experiments—where a specific gene is inactivated—the results were highly successful. When targeting the Gasdermin D gene using 4-week-old donor females, the authors report an 88.8% success rate in pups via microinjection [Figure 1d]. Similarly, targeting the Trpm5 gene yielded success rates of 86% via microinjection and 84% via electroporation [Table 2C]. Interestingly, 4-week-old females produced a higher number of gene-edited pups per female than 6-week-old females. This offers a significant advantage in resource management.

The most complex task was gene knock-in (KI). This is the precise insertion of new genetic material. The researchers targeted the ACE2 gene (a receptor used by the SARS-CoV-2 virus) to introduce human-like amino acid substitutions. They compared two types of templates for this insertion: short oligonucleotides and longer single-stranded DNA (ssDNA). The authors find that electroporation with ssDNA achieved a 30–33% success rate. In contrast, using oligonucleotides dropped the efficiency to just 12.5% [Table 3]. This confirms that for complex insertions, the length of the homology arms (matching DNA sequences that guide the insertion) is a decisive factor.

Limitations of the streamlined approach

While the protocol is a major advancement, it is not a universal solution. The authors identify several constraints:

• Cargo Size Constraints: Electroporation is excellent for high-throughput manipulation. It can process up to 150 embryos at once. However, it cannot deliver large plasmids or very large DNA fragments. For massive genetic constructs exceeding 10–15kb, direct pronuclear microinjection remains necessary.
• Cost of Reagents: Electroporation requires larger volumes of the CRISPR/Cas9 "injectables" (the biochemical reagents). This may increase the per-embryo cost in high-volume settings.
• Targeting Specificity: The study notes that cytoplasmic microinjection was entirely unsuccessful. It yielded a 0% success rate for Gasdermin D targeting. This highlights the absolute necessity of nuclear delivery in the NOD strain.

The verdict: A new standard for NOD modeling

For laboratories specializing in immunology or infectious disease research, this paper provides a clear path forward. By focusing on 4-week-old females and using a strictly timed 46-hour hormonal window, the authors have transformed a two-year breeding ordeal into a three-month procedure.

The methodology is robust. It provides high-efficiency alternatives for both simple knockouts and complex humanized knock-ins. The choice between microinjection and electroporation will still depend on the genetic payload and required throughput. However, the fundamental barrier—the difficulty of obtaining high-quality NOD embryos—has been effectively addressed.

Figures from the paper